Excel Venture Management United States

Excel Venture Management is a venture capital firm that was founded in 2008 and is based in Boston, Massachusetts. The firm has managed one fund with committed capital of $125 million, and the firm is currently raising the second fund. Excel Venture Management seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $3 million to $ 5million. The firm plans to invest in 4-5 companies over the next 6-9 months and prefers to invest in companies based in US.

Year Founded
2008
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Eric Zimmerman
Kevin Liang

Greenhouse Capital Partners United States

Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.

Eric Desai
Principal 

HealthQuest Capital United States

Sofinnova Ventures was founded in 1974 and is based in Menlo Park, CA. The firm has approximately $1b of assets under management, and makes life science investments from two fund families; the main Sofinnova Ventures fund and Sofinnova HealthQuest Capital. Sofinnova Venture Partners IX closed at $500 million in 2014, and the debut HealthQuest fund closed at $110 million in 2014. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. Sofinnova Ventures plans to make 4-6 new investments in life science companies in 2014. 

The Sofinnova Ventures main fund invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-30m. The fund invests in companies based in North America or Europe. 

HealthQuest Capital invests in non-biopharmaceutical life science and medtech companies and typically makes initial investments of $2-3m, with the potential for total investments of $5-6m. HealthQuest Capital is a venture growth fund focused on commercial-stage technologies, and only invests in companies headquartered in North America (particularly the US Southeast or West Coast).

Garheng Kong
Garheng Kong
Managing Partner 
Randy Scott
Randy Scott
LinkedIn logo Partner 

Horizon Technology Finance United States

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Year Founded
2003
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jerry Michaud

Immusoft Corporation United States

Immusoft’s mission is to develop a breakthrough platform for delivering targeted medicines — programming a patient’s own cells to become miniature drug factories.

Our technology instructs a patient's cells to constantly secrete gene-encoded medicines (biologics). It will enable new treatments by solving current delivery limitations and production challenges. We are initially targeting orphaned diseases. 

Immusoft’s platform can program cells to continually produce and secrete therapeutic proteins and rare antibodies that have been impossible to elicit with a vaccine. This approach makes possible treatments that are otherwise impractical due to short halflife, injection site reactions, production challenges or a small market size. It offers many of the benefits of traditional approaches and modern gene therapies with less risk and greater control.

Immusoft has received grants from the National Institutes of Health and Peter Thiel's Breakout Labs as well as support from private investors, including the former head of preclinical development at Seattle Genetics. We have an exclusive license option on our core technology from Caltech and have filed two additional patents covering our extensive modifications to the technology.

ISP technology could replace a lifetime of infusions with a patient’s own drug-producing cells.

Website:
www.immusoft.com
Year Founded
2009
Biotech Phase of Development
Technology Overview
Turning patients' cells into drug factories
Alliance & Collaborations
Fred Hutchinson Cancer Research Center, Discovery Genomics, Inc, University of Minnesota, The Ragon Institute, University of California San Francisco
Supporting Metrics or Evidence
Late-stage preclinical
Current Financing Needs
$3 to >$20M
Current Timeline
Preparing IND for clinical trial
Current Investors
Breakout Labs, Founders Fund Science, several angels
IP Status
multiple patents filed worldwide
Recent Milestones
GMP scale-up in preparation for clinical trial; engaging the FDA for Investigator-initiated IND; use of Sleeping Beauty Transposon non-viral vector
Management Team Highlights
Matthew Scholz (Founder and CEO) – Seasoned startup executive; founded and exited Point B Telematics. Eric Herbig, Ph.D., M.B.A. (CSO) – 15+ years of research experience and significant commercialization and management expertise. Zach Hall (Dir. of Operations) – Co-founder and operations director at two previous biomedical startups. Mei Xu, Ph.D. (Dir. of Research) – Molecular biologist with extensive research experience.
J. Zach Hall
Director of Operations 
Matthew Scholz
CEO 

Joslin Diabetes Center United States

Joslin Diabetes Center is a foundation based in Boston, Massachusetts that was founded in 1898, and is the world's largest diabetes and clinical care organization.

Nandan Padukone
Vice President, Office of Commercialization & Ventures 

Jump Capital United States

Jump Capital was founded in 2012 and is based in Chicago, with an additional office in San Francisco. The firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, Jump Capital typically allocates $2-15 million, and prefers to invest in Series B-C rounds. Jump Capital invests in the USA and Canada, and has previously invested in 6 healthcare companies.

Jump Capital invests in medical devices, diagnostics, digital and mobile health, and healthcare services. The firm is open to opportunities in any clinical indication. Jump Capital is only interested in devices and diagnostics that have in-human data.

Dr Garrett Vygantas
LinkedIn logo Partner 

JVC Investment Partners United States

JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

David Jonas
Founder, President & CEO 
Jonathan Jonas
Partner 

Life Science Angels

Life Science Angels Inc was founded in 2004 and is based in Sunnyvale CA. The group makes early-stage equity investments in a wide range of life science companies. Life Science Angels invests primarily in California but is open to investing out of state provided a round is being syndicated with a local angel group. Life Science Angels does not rule out investing outside the USA but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied but are usually of about $2-$6, Life Science Angels usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Dr Faz Bashi
Chair Digital Health & Sciences 
Karl Handelsman
Founder & Chairman 
Allan May
Founder 

Life Science Nation

Life Science Nation (LSN) is the premier sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient. 

Biotech Phase of Development
Medtech Phase of Development
Unique Capabilities

Life Science Investor Profiles, LSN has sourced validated and maintains the largest global database of investor profiles. LSN defined 10 categories of Life Science Investor;

·         Private Equity

·         Venture capital

·         Family Offices

·         Corporate VC

·         Angel Groups

·         Large Pharma/ Biotech

·         Alternative Institutional Investors: Pensions, Endowments

·         Endowments/Foundations

·         Hedge Funds

·         Government Grants

Marketing Services, LSN consults on branding, messaging, and outbound marketing strategies. This includes developing a tagline, elevator pitch, executive summary, corporate power point presentation, and new or updated website design to fit your brand and message. LSN will develop a Global Target List of prequalified candidates to target for marketing initiatives.

Alejandro Zamorano
Tom Crosby
David Mejia
Gwen Lamar
Danielle Silva
Jack Fuller
Marlo Galvez
Laura Chess
Dennis Ford
BIO

Dennis is the founder and CEO of Life Science Nation (LSN) and creator of the Redefining Early Stage Investment (RESI) conference series. Most recently, he launched a broker-dealer entity called Boston Innovation Capital (BIC).

Dennis’s expertise is in creating and facilitating interactive dialogue between buyers and sellers. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. LSN provides a Match.com-like platform of product and services for scientist/entrepreneurs and early stage investors to connect with each other.

Dennis is the author of The Peddler’s Prerogative, The Fund Manager’s Marketing Manifesto, and most recently, The Life Science Executive’s Fundraising Manifesto. Dennis is an expert in sales, marketing, and business development. Dennis has distinct value in understanding the world of global alternative life science investors and how that relates to financing early stage technologies.